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A B S T R A C T
Introduction: Female hemophilia is an intriguing rare disorder and few larger reports on its genetic etiology are
available. While historically the diagnosis was satisfactorily reached by factor VIII activity assays, the clinical
and potentially therapeutic heterogeneity of female hemophilia calls for comprehensive molecular diagnosis in
each case. Currently, the genetic investigations are not a part of routine, state-funded, diagnostics in Poland, and
thus molecular epidemiological data are missing.
Aim: We set out to perform a comprehensive genetic analysis of Polish females with hemophilia A.
Patients/methods: Eighteen females with hemophilia A (including 2 with severe and 5 with moderate hemophilia
phenotype) consented for genetic diagnostics. To establish F8 mutations, we used next-generation sequencing of
a panel of genes associated with hematological disorders, standard assays for recurrent intragenic F8 inversions
and MLPA when deletions were suspected. When appropriate we also used karyotyping, genomic microarrays
and X chromosome inactivation assays.
Results: While abnormally skewed X-chromosome inactivation combined with a F8 variant on the active allele
was, as expected, the most common genetic etiology, a number of other genetic scenarios were unraveled. This
included: misdiagnosis (molecular diagnosis of vWd), Turner syndrome, compound heterozygosity and androgen
insensitivity syndrome (a phenotypical 46,XY female with a novel androgen receptor gene mutation). We report
3 novel F8 mutations.
Conclusion: Every case of female hemophilia warrants full genomic diagnostics, as this may change the diagnosis
or reveal broader morbidity than a coagulation disorder (Turner syndrome, androgen insensitivity, or cardio-
vascular morbidity that we described previously in a SHAM syndrome carrier).
1. Introduction
The molecular pathogenesis of hemophilia A in males has been
known for a long time and hemophilia A is a model monogenic disease,
but there is a wide variability in the genetic defects in females with
hemophilia [1,2]. Although skewed X chromosome inactivation (XCI) is
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believed to be the most common cause of X-linked disease in women,
there are few studies and thus no reliable data on the relative frequency
of skewed XCI versus various genomic events leading to loss of F8 ex-
pression from both alleles. There might be a bias for reporting skewed
XCI if genetic defects are difficult to register in a particular case. Also,
severe or moderate hemophilia must be a consequence of an extremely
abnormal X chromosome inactivation pattern, itself likely caused by
genomic lesions of X chromosome or mutations in genes active in XCI
[1–3]. Occasionally, as we previously demonstrated, the hemophilia-
causative genomic defects may result in phenotypes and morbidity
broader than the coagulation defect and their identification will facil-
itate proper management (as exemplified by a contiguous gene syn-
drome associated with hemophilia A that we previously described)
[4–6]. Also, there is an increasing therapeutic heterogeneity and the
treatment choice in special circumstances such as hemophilia in a fe-
male should be supported by exhaustive diagnostics [7,8]. Lastly, we
believe every patient with rare disease deserves thorough genetic di-
agnostics to enable genetic counselling and several clinical re-
commendations advocate for genetic work-up in females with bleeding
disorders [9]. Currently, genetic testing in the setting of hemophilia is
not routine and state-funded in Poland. Having this in mind, we in-
itiated a nationwide survey for genetic causes female hemophilia A to
assess the prevalence of the disorder and potentially uncover novel
disease-associated genomic alterations. Prior to this study, we were not
aware of any previous reports on molecular causes of this rare disease in
Poland apart from our previous publication [5].
2. Materials and methods
2.1. Patients
18 females, including one pair of siblings, with hemophilia A were
recruited via the centers providing hemophilia services in Poland (we
approached 15 pediatric and 16 adult departments). Patients char-
acteristics are presented in the Results section. Appropriate ethical
approval was obtained from the Local Ethical Board at the Medical
University of Lodz (decision No RNN/238/17/KE).
2.2. DNA extraction
Genomic DNA was extracted from peripheral blood samples of 18
patients using FlexiGene DNA Kit (Qiagen, USA) and checked for
quality using Qubit v.3 (Thermo Fisher Scientific, USA).
2.3. Next-generation sequencing
The Next Generation Sequencing was performed using custom de-
signed SureSelect QXT panel (Agilent Technologies, USA) comprising
535 genes related to hematological diseases, including Hemophilia A
and vWd, as well as FVFVIII deficiency, as described in our two pre-
vious publications. Briefly, the DNA libraries were prepared according
to manufacturer's protocols and sequenced on a Next Seq 550 (Illumina,
USA) in the process of 300 bp paired-end run. The data analyses of the
target regions were performed using BWA Genome Alignment Software
and the GATK Variant Caller algorithms and mapped to the human
genome reference sequence GRCh37/hg19. The results were next ana-
lyzed using Variant Studio v. 3.0 (Illumina, USA) and Integrative
Genomics Viewer v.2.3. The filtering criteria included coverage with at
least 20 reads and allele frequency below 0.01. All filtered variants
were investigated by several bioinformatics tools: SIFT, Mutation
Taster, and PolyPhen-2. The pathogenicity of the revealed variants was
estimated based on ClinVar, ExAC, OMIM, HGMD, Varsome and LOVD
databases. The detected variants were verified by direct DNA sequen-
cing. Standard PCR conditions were used with the primers designed
using Primer 3 v. 0.4.0. Products were sequenced on ABI 3130 4-ca-
pillary sequencer (Applied Biosystems, USA) and the results were
analyzed using Sequencher v. 5.0.
2.4. MLPA
Targeted copy number screening of F8 exons was performed in the
cohort using multiplex ligation-dependent probe amplification (MLPA),
which is a multiplex PCR (polymerase chain reaction)-based technique
in which probes hybridized to the sample DNA, are amplified using only
one PCR primers pair. A simultaneous and semi-quantitative amplifi-
cation is used to determine the relative copy number of each DNA se-
quence in a single multiplex PCR-based reaction. The commercially
available SALSA MLPA P178 F8 probemix kit (MRC–Holland, the
Netherlands) was used for MLPA reactions as per manufacturer's pro-
tocol. Briefly, probe mix and hybridization buffer (MRC-Holland) were
added in equal amounts to 150 ng of genomic DNA followed by heat
denaturation and overnight hybridization of the probes at 60 °C.
Subsequently, ligation was performed and the ligation products were
amplified by PCR using a 6-FAM fluorophore-labeled primer set (MRC-
Holland). The different length products after PCR were separated on an
automated capillary sequencer (Applied Biosystems, USA). The size and
peak areas for each probe were quantified and analyzed by data ana-
lysis software (GeneMarker v2.7.0., Softgenetics, USA).
2.5. F8 intron 22 and intron 1 inversion assays - inverse shifting-polymerase
chain reaction (IS-PCR)
F8 intron 22 and intron 1 inversion assays with Inverse shifting-
polymerase chain reaction (IS-PCR) were all conducted as previously
described in our study of 101 Polish boys with hemophilia A [10] ac-
cording to a slight modification of an inverse shifting-polymerase chain
reaction (IS-PCR) described originally by Rossetti et al. [11]. 2 μg of
genomic DNA was digested with 20 units of BclI (ThermoFisher Sci-
entific, USA) at 55 °C over 4 h in 50 ul. Digested DNA was isolated using
phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma-Aldrich). The aqu-
eous phase was removed and isopropanol (Sigma-Aldrich, Germany)
precipitated DNA were washed with 75% cold ethanol and air-dried.
The restriction fragments were circularized with 400 units of T4 DNA
ligase (EURx) in 25 μl at 16 °C overnight that represent templates for a
standard PCR analysis. Later DNA was extract as above and the circu-
larized DNA was used in IS-PCR. Primer sequences are shown in Sup-
plementary Table 1. The PCR conditions were as follows: 35 cycles,
each cycle consisting of 1 min of denaturation at 95 °C, 30 s for an-
nealing at 56 °C, and 30 s at 72 °C for extension. Cycling was preceded
by 95 °C for 15 min, and followed by 5 min at 72 °C. IS-PCR products
were analyzed with GelRed Nucleic Acid Gel Stain (Biotium) on 2%
agarose gel electrophoresis.
The Inv22 diagnostic test uses four primers (IU, 2U, 3U and ED) to
permit a diagnosis of the Inv22-1 (distal pattern), Inv22-2 (proximal
pattern) and normal allele. The complementary test allows further
discrimination between the pairs that remained unclassified after the
Inv22 diagnostic test – wildtype allele (normal) and Dup22 by gaining
the 559 bp (Supplementary Table 2). The Inv1 diagnostic test uses tree
primers (1-IU, 1-ID and 1-ED). IS-PCR products of 304 bp and 224 bp
indicated the normal and the Inv1 allele, respectively (Supplementary
Table 3).
2.6. X chromosome inactivation (XCI) assay
X chromosome inactivation analysis based on methylation specifi-
city of restriction enzymes at polymorphic short tandem repeats (STR)
in a chosen X linked marker was performed as described in our previous
publications [5,12]. The two X chromosomes in human females can be
distinguished from each other by using a polymorphic CAG repeat in
exon 1 of AR (human androgen receptor gene) in Xq12. The assay is
based on selective activity of HpaII restriction endonuclease on un-
methylated but not methylated DNA and remains relatively standard in
S. Janczar, et al. Thrombosis Research 193 (2020) 9–14
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X chromosome inactivation analysis. The XCI study included 20 healthy
females who had blood drawn for various diagnostic procedures and
who agreed for their blood samples to be anonymized and used as re-
ference for genomic experiments.
2.7. HpaII and RsaI digestion of DNA
Genomic DNA (100 ng) was digested with either 20 U RsaI alone or
20 U RsaI with 20 U HpaII (both enzymes with Thermo Fisher
Scientific). RsaI digest genomic DNA, but does not affect fragment size,
as the PCR amplified region does not contain an RsaI cutting site, so it
was used for technical reasons. Both reaction was performed in a total
reaction volume of 10 μl and incubated at 37 °C for 16 h. Restriction
enzymes were inactivated by incubation at 65 °C for 20 min and stored
at 4 °C.
2.8. PCR amplification and fragment analysis
PCR amplification was performed using 25 ng undigested DNA or
2,5 μl of HpaII and RsaI digested DNA, 200 μM of each dNTP (Roche),
1× reaction buffer, 0.5 U of Hot Start Taq DNA polymerase (Qiagen),
0.1 μM of each primer (forward and reverse). The forward primer was
labeled with FAM on the 5′ end; AR-F (5′-TCCAGAATCTGTTCCAGAG
CGTGC-3 2032′) and AR-R (5′-GCTGTGAAGGTTGCTGTTCCTCAT-3′).
These primers flank a highly polymorphic CAG repeat region in exon 1
of AR. The PCR parameters were as follows: 95 °C for 15 min and
35 cycles (95 °C for 20 s, 67 °C for 20 s, 72 °C for 25 s), followed by
72 °C for 7 min. The PCR products were separated on an ABI 3130 DNA
sequencing analyzer (Applied Biosystems) and analyzed by GeneMarker
software v2.7.0 (SoftGenetics). The digestion process preferentially
degrades activated (unmethylated) over inactivated (methylated) DNA.
Undigested DNA is preferentially amplified and produces larger peak
heights. The peak height values for digested DNA are normalized using
peak height values for the undigested DNA for each subject. The X -
inactivation ratios (X1:X2) represent the level of inactivation of the
smaller compared to that of the larger allele. The X-inactivation level of
each allele was calculated using peak heights with the formulas:
X1 = (d1/u1)/[(d1/u1) + (d2/u2)]; X2 = (d2/u2)/[(d1/u1) + (d2/
u2)]; d1 – peak height of digested DNA from the first allele and u1 –
peak height of undigested DNA from the first allele; d2 – peak height of
digested DNA from the second allele and u2 – peak height of undigested
DNA from the second allele.
2.9. Karyotyping (G-binding)
The process of generating a karyotype was based on culturing the
cells from whole blood stimulated with phytohemagglutinin (PHA).
After a period of cell growth and multiplication (72 h; 37 °C, 5% CO2),
dividing cells were arrested in metaphase by addition of colchicine,
which poisons the mitotic spindle. Next the cells were treated with a
hypotonic solution, destroying the nuclear membrane and releasing
chromosomes. Subsequently metaphase chromosomes were fixed,
dropped on a glass slide, and treated with trypsin and Wright blue so-
lution. Karyotyping was performed with use of CytoVision software and
light microscope Olympus BX51.
2.10. SNP genomic microarrays
SNP microarray analysis of the extracted DNA from the peripheral
blood samples was performed using the Affymetrix CytoScan HD plat-
form (Affymetrix), which containsapproximately 2.6 million markers,
and provide an average resolution of the array to be one marker per
3Kb in the targeted regions and one marker per 5Kb in the backbone.
Purified DNA was fragmented, amplified and hybridized according to
the Affymetrix Cytogenetics Assay Protocol. The scanning was per-
formed using the GeneChip Scanner 3000DX (Affymetrix) and data
obtained were analyzed using the ChAS v.3.3 software (Affymetrix).
2.11. Polish reference population
We also accessed an anonymized database of 825 female individuals
that we prepared for our previous publication, whose genetic diag-
nostics for indications other than hemophilia or other bleeding ten-
dency included gene panel of whole exome next-generation sequencing,
and who consented for further scientific use. This cohort served for our
study as a genetic reference population of Polish females. No pheno-




Table 1 presents the characteristics of females, with FVIII activity
ranging from 0.5 to 40%, included in the study. VWF:Ag and VWF:RCo
values were reported as normal for all patients by all referring centers.
3.2. The genetic analysis of 18 Polish females with hemophilia A yields
known and novel F8 variants
We have identified likely causative F8 gene variants (nucleotide
variants or rearrangements) in all cases in our study, apart from one
subject that turned out to be suffering from von Willebrand disease type
2N. All variants determined with NGS were confirmed with Sanger
sequencing. We also performed intron 22 and 1 inversion analysis in all
cases. No deletion mutations were found. In total in 17 females with
hemophilia there were 18 pathogenic F8 variants (on 32 X chromo-
somes as there was one 45,X and one 46, XY case as described below),
two of these were identical (siblings). These 18 variants included 8
cases of intron 22 inversion and 9 different pathogenic nucleotide
variants. Nucleotide variants were compared against variants reported
in severe hemophilia B in EAHAD (European Association for
Hemophilia and Allied Disorders), CHAMP (CDC Hemophilia Mutation
Project) and CHAMP US databases [13]. Table 2 presents variants
present in our patient population that are identical to F8 variants al-
ready reported in hemophilia A genetic databases or our previous
analysis of Polish boys with hemophilia A [10] and 3 novel variants that
were previously not described.
3.3. Six different molecular patterns leading to hemophilia A phenotype in
18 Polish females
We observe 6 different molecular patterns leading to hemophilia A
phenotype in 18 Polish females. These include 1) misdiagnosis, 2)
carriers of one F8 defect with marginally depressed FVIII activity and
no skewed XCI, 3) 45,X karyotype associated with F8 defect, 4) 46,XY
androgen insensitivity syndrome associated with F8 defect are de-
scribed below, 5) compound heterozygosity for F8 mutation, 6) F8
defects associated with abnormally skewed X chromosome inactivation.
Table 1
Basic demographic and clinical data of the study population.
Current age (years-median, range) 11 (2–64)
Phenotype (severe/moderate/mild) 2/5/11
Factor VIII activity (%-median, range) 9.6 (0.5–40)
Ethnicity (Caucasians/others) 18/0
FVIII prophylactic treatment (yes/no) 1/17
Factor VIII inhibitor (yes/no) 1/17
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3.4. Misdiagnosis
In one patient with FVIII activity of 35.8% we found no sequence
alterations of the F8 genes, but instead the patient was demonstrated to
be homozygotic for p.Arg854Gln VWF variant consistent with type 2 N
von Willebrand disease. vWf antigen level was 116% (normal vWf an-
tigen and vWf:RCO are typical for vWd type 2 with homozygotic
Arg854Gln mutation [14]). No pathogenic VWF variants were found in
the remaining females. No rare, low frequency or potentially patho-
genic variants in genes associated with combined deficiency of FV and
FVIII (LMAN1 and MCFD2) were found in any of the patients excluding
F5F8D diagnosis.
3.5. Carriers of one F8 defect with marginally depressed FVIII activity
In 2 patients with only marginally abnormal FVIII activity (38.8%
and 40%) the analysis yielded F8 mutation on only 1 allele (intron 22
inversion) and no skewed X chromosome inactivation. This is consistent
with the observation that some hemophilia carriers have FVIII activity
slightly below normal levels rather than expected 50%.
3.6. Turner syndrome
One patient (FVIII activity 4.5%) was demonstrated to suffer from
Table 2
F8 mutations in females with hemophilia A reported in EAHAD, CHAMP and CHAMP US databases or our previous study of 101 boys (normal font) and novel F8
mutations (absent in EAHAD, CHAMP and CHAMP US databases and our previous study – in bold).
Number of patients HGVS coding sequence
(NM_000132.3)
HGVS protein sequence (NP_000123.1) Database phenotype Allele frequency among female carriers in Polish
reference population
1 c.677G > A p.Ser226Asn – 0
1 c.1271 + 1G > T splice site variant Severe 0
1 c.1812G > C p.Trp604Cys Severe 0
1 c.2078C > T p.Ser693Leu Moderate 0
1 c.4379dupA p.Asn1460LysfsTer2 Moderate/severe 0
1 c.5405A > G p.Tyr1802Cys Mild/moderate 0
1 c.6118T > C p.Cys2040Arg – 0
1 c.6509delT p.Leu2170CysfsTer16 – 0
2 (siblings) c.6929C > T p.Thr2310Ile Mild 0
Fig. 1. Clinical and genetic characteristics and mode of inheritance in a family of a proband with androgen insensitivity syndrome and severe hemophilia A.
Table 3
The characteristics of patients in whom XCI plays a causative role (random XCI
was defined as 50%: 50% to 64%: 36%, mildly skewed as 65%: 35% to 80%:
20%, and severely skewed as>80%: 20%).
FVIII activity F8 mutation XCI pattern
0.5 Trp604Cys Severely skewed
2 Intron 22 inversion Severely skewed
3 Ser226Asn Severely skewed
6.9 Ser693Leu Severely skewed
7 Intron 22 inversion Severely skewed
12.3 Intron 22 inversion Mildly skewed
23.4 Intron 22 inversion Mildly skewed
24.5; 34.2 (siblings) Thr2310Ile Severely skewed
33.1 Asn1460LysfsTer2 Mildly skewed
40 Intron 22 inversion Mildly skewed
S. Janczar, et al. Thrombosis Research 193 (2020) 9–14
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Turner's syndrome (monosomy X) and a be a carrier of a novel missense
p.Cys2040Arg F8 mutation.
3.7. 46,XY androgen insensitivity syndrome
Another patient (FVIII activity< 1%) was shown to have a 46,XY
karyotype androgen insensitivity syndrome caused by a novel AR mu-
tation (NM_000044.3:c.2319-2A > G splice site acceptor mutation)
combined with F8 gene intron 22 inversion. This is the only patient
with factor VIII inhibitor in our study. Prior to the study this 55-year-
old nullipara was not aware of the 46,XY karyotype and did not consent
for further gynecological and endocrine work-up once received the
genetic diagnosis. We also performed genetic analysis in the brother of
the proband, who also suffers from severe hemophilia A, and this al-
lowed us to conclude this AR variant is a de novo mutation (the gen-
otype of the mother can be established based on the data from off-
spring, Fig. 1). There are already some reports of hemophilia in females
with 46,XY karyotype but most of them date back several decades
[15–17].
3.8. Compound heterozygosity
One patient (FVIII activity 4%) presented with 2 pathogenic F8
point mutations: novel nonsense p.Leu2170CysfsTer16 and previously
reported missense p.Tyr1802Cys.
3.9. Skewed X chromosome inactivation combined with an F8 mutation is
causative in most cases
In 10 females hemophilia A phenotype could be ascribed to a mu-
tation/rearrangement in F8 combined with abnormally skewed X
chromosome inactivation. This is presented in Table 3. This must be
acknowledged that XCI was assessed from peripheral blood leukocytes,
as FVIII producing tissue is not available for practical and ethical rea-
sons. Fig. 2 presents an example of XCI analysis with extreme skewing.
The patient with 0.5% FVIII activity and p.Trp604Cys mutation is the
only one receiving FVIII prophylaxis in our cohort (because of bleeding
to a target joint) (Fig. 2).
4. Discussion and conclusion
We provide a first molecular epidemiologic data from a nationwide
survey of the clinical features and genetic etiology in Polish women
with hemophilia A. Regarding F8 defects, similar to reports from other
ethnic groups there is a high prevalence of private mutations, these
including 3 novel disease-coding F8 variants, so far not found in males.
It is possible to speculate on the phenotype of the 3 novel mutations.
Asn1460LysfsTer2 was also found in proband's son suffering from se-
vere hemophilia, p.Cys2040Arg likely leads to phenotype of moderate
hemophilia (FVIII activity of 4,5% in Turner syndrome patient),
Ser226Asn seem to lead to severe or moderate phenotype (FVIII activity
of 3% in a female with extremely skewed XCI). Most importantly, we
identified a wide and frequently surprising range of defects leading to
the phenotype of hemophilia A in females. Of particular interest was a
patient with a 46,XY karyotype and a novel AR mutation leading to
androgen insensitivity syndrome. In general, the molecular events
leading to female hemophilia, especially moderate/severe must be
complex and may be also causative for other morbidity. Full description
of the frequently surprising comorbidities and the association of he-
mophilia-causative genomic defects with phenotypes broader than the
coagulation defect may facilitate proper management (as exemplified
by a contiguous gene syndrome associated with hemophilia A that we
Fig. 2. XCI analysis based on the analysis of methylation specificity of HpaII restriction enzyme at polymorphic short tandem repeats in the AR gene in a patient with
extreme XCI skewing.
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previously described) [4–6].
This level of genomic complexity is similar in our recent report of
females with hemophilia B in Poland although unlike in hemophilia B,
in this cohort of females with hemophilia A we identified no chromo-
somal translocations, which seem to be causative for a proportion of
females with hemophilia B [12]. The genetic diagnosis of female he-
mophilia A may have impact on clinical treatment as well as genetic
counselling and the emerging six molecular patterns we describe plus
chromosomal translocations and gross deletions form a catalogue of
genomic events to be investigated. Skewed XCI as a cause for X-linked
congenital disorders in females should be interpreted with caution
following exhaustive genetic work-up.
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